Oramed Pharmaceuticals Inc ORMP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $3.80
- Day Range
- $3.81–3.93
- 52-Week Range
- $1.98–5.01
- Bid/Ask
- $3.76 / $3.88
- Shares Outstanding
- 40.93M
- Market Cap
- $158.38M
- Volume/Avg
- 112,827 / 157,385
Key Statistics
- Price/Earnings (Normalized)
- 3.20
- Price/Sales
- —
- Dividend Yield (Trailing)
- 6.82%
- Dividend Yield (Forward)
- 6.82%
- Total Yield
- 9.45%
Company Profile
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 13
- Website
- https://www.oramed.com
Valuation
|
Metric
|
ORMP
|
|---|---|
Price/Earnings (Normalized) | 3.20 |
Price/Book Value | 0.65 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
ORMP
Financial Strength
|
Metric
|
ORMP
|
|---|---|
Quick Ratio | 6.23 |
Current Ratio | 6.45 |
Interest Coverage | — |
Quick Ratio
ORMP
Profitability
|
Metric
|
ORMP
|
|---|---|
Return on Assets (Normalized) | 1.47% |
Return on Equity (Normalized) | 1.61% |
Return on Invested Capital (Normalized) | −6.40% |
Return on Assets
ORMP
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Znzrrtp | Yszqnm | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Pvbjtvkc | Yjylfl | $64B | |||
| argenx SE ADR
ARGX
| Bgrbmdnz | Xvkyt | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Lczzgwtw | Lqtbjx | $38B | |||
| Royalty Pharma PLC Class A
RPRX
| Zllhqxqzt | Twpjmh | $24B | |||
| BioNTech SE ADR
BNTX
| Gngzjqw | Gdz | $23B | |||
| Incyte Corp
INCY
| Zmqhftxvt | Fcxn | $22B | |||
| Moderna Inc
MRNA
| Hckjzsfdf | Xytgj | $20B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Rzlqfchkz | Hqtn | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Gfkvqgqb | Yzkrw | $13B |
United States